louisiana semaglutide nausea class action She had been taking Ozempic for a few months, starting in Ozempic Lawsuit [2026 Update]

The researchers noted several important limitations, including the retrospective observational design, inability to verify medication adherence, and potential residual confounding despite propensity matching

Use that kind of information to prepare better questions, not to self-treat

Semaglutide (the active ingredient in brand-name drugs Ozempic, Rybelsus, and Wegovy) is a GLP-1 receptor agonist, antidiabetic, and weight loss drug

One critique of the SURPASS II trial is that tirzepatide was not compared to the full 2.4mg dose of semaglutide (Wegovy) approved for weight loss

spending on GLP-1 medications rose from roughly $13 billion in 2018 to nearly $72 billion in 2023, and insurers are responding to that pressure, not to patient need

Medicare does not currently cover GLP-1s for weight loss alone only for diabetes, cardiovascular disease, or sleep apnea but a GLP-1 demonstration program for obesity is expected to begin in mid-2026 for some Medicare enrollees